Kronos Bio, Inc.(KRON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KRON Kronos Bio, Inc.

Halted 12-26 09:21:53 EST

0.8800

+0.0000

0.00%

High0.8800	Low0.8800	Vol0.00
Open0.8800	D1 Closing0.8800	Amplitude0.00%
Mkt Cap53.73M	Tradable Cap38.67M	Total Shares61.05M
T/O47.16K	T/O Rate0.00%	Tradable Shares43.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KRON","market":"US","secType":"STK","nameCN":"Kronos Bio, Inc.","latestPrice":0.88,"timestamp":1750449600000,"preClose":0.88,"halted":3,"volume":0,"delay":0,"floatShares":43941442,"shares":61051344,"eps":-1.067782,"marketStatus":"Halted","change":0,"latestTime":"12-26 09:21:53 EST","open":0.88,"high":0.88,"low":0.88,"amount":47163.8963,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.067782,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766759400000},"marketStatusCode":1,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":0.88,"volumeRatio":0},"requestUrl":"/m/hq/s/KRON","defaultTab":"news","newsList":[{"id":"2544175031","title":"Kronos Bio Inc. Completes Merger with Concentra Biosciences, Becoming a Wholly Owned Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2544175031","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544175031?lang=en_us&edition=fundamental","pubTime":"2025-06-20 22:53","pubTimestamp":1750431200,"startTime":"0","endTime":"0","summary":"Kronos Bio Inc. announced the completion of its merger with Concentra Biosciences, LLC. As per the terms of the agreement, Concentra's wholly owned subsidiary, Concentra Merger Sub IV, Inc., completed a tender offer to acquire all outstanding shares of Kronos Bio for $0.57 per share in cash, along with a non-transferable contractual contingent value right per share. The tender offer expired on June 18, 2025, and successfully resulted in the acquisition of approximately 72.90% of Kronos Bio's outstanding shares. Following the satisfaction of all conditions, the merger was finalized on June 20, 2025, with Kronos Bio continuing as a wholly owned subsidiary of Concentra.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. publis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL8l543Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KRON"],"gpt_icon":0},{"id":"2541893449","title":"Deborah Knobelman, President & Interim CEO, Reports Disposal of Kronos Bio Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541893449","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541893449?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:48","pubTimestamp":1749242907,"startTime":"0","endTime":"0","summary":"Deborah Knobelman, President & Interim CEO of Kronos Bio Inc., reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL81pPf8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Deborah Knobelman, President & Interim CEO, Reports Disposal of Kronos Bio Inc. Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRON","BK4505","BK4139"],"gpt_icon":0},{"id":"2541002244","title":"BRIEF-Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2541002244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541002244?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:22","pubTimestamp":1749122544,"startTime":"0","endTime":"0","summary":"BRIEF-Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC FilingKronos Bio Inc KRON.O:KRONOS BIO INC - TERMINATES OFFICE LEASE AT 301 BINNEY STREET - SEC FILINGKRONOS BIO INC - TO PAY $22.5 MILLION FOR LEASE TERMINATION - SEC FILINGKRONOS BIO INC - ESTIMATES $18.2 MILLION IN COST SAVINGS FROM LEASE TERMINATION - SEC FILINGSource text: [ID:n0001213900-25-051350]Further company coverage: KRON.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S70X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRON","BK4505"],"gpt_icon":1},{"id":"2541022580","title":"Kronos Bio Inc - to Pay $22.5 Mln for Lease Termination - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2541022580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541022580?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:04","pubTimestamp":1749121457,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S70X0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRON","BK4505","BK4139"],"gpt_icon":0},{"id":"2532288592","title":"Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2532288592","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532288592?lang=en_us&edition=fundamental","pubTime":"2025-05-02 01:25","pubTimestamp":1746120341,"startTime":"0","endTime":"0","summary":"Kronos Bio  said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.A Concentra subsidiary is expected to commence a tender offer by May 15.The transaction is anticipated to close by mid-2025, Kronos Bio said.Shares of Kronos were down nearly 23% in recent trading.Price: 0.69, Change: -0.20, Percent Change: -22.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KRO","KRON","BK4505","BK4090"],"gpt_icon":0},{"id":"2532077903","title":"Kronos Bio Agrees to Be Acquired by Concentra Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2532077903","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532077903?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:08","pubTimestamp":1746104880,"startTime":"0","endTime":"0","summary":"Kronos Bio said it has agreed to be acquired by Concentra Biosciences at 57 cents per share and contingent rights for proceeds from sales of its product candidates.The biotechnology company said Thursday that along with 57 cents a share in cash, investors will get the non-tradeable contingent value right to receive 50% of the proceeds from the sale of KB-9558 and KB-7898 within two years of closing and all proceeds from the sale of KB-0742, lanraplenib and entospletinib prior to closing.The rights also give shareholders all cost savings realized before closing, 80% of cost savings realized between the merger closing date and the second anniversary of that date, and half of cost savings realized in the year that follows.Kronos's board has approved the agreement and thinks it is in the best interest of all shareholders.Concentra will commence a tender offer for Kronos shares by May 15 and close the offer once it gets at least a majority of outstanding shares. The closing is also conditio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRON","KRO","BK4505","BK4139","BK4090"],"gpt_icon":0},{"id":"2532072479","title":"Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2532072479","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532072479?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:30","pubTimestamp":1746102638,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. , a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right . The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL8JbRYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRON","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","BK4139","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","BK4505","NDAQ"],"gpt_icon":0},{"id":"2532749450","title":"Kronos Bio Inc - Concentra to Acquire Kronos Bio for $0.57 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2532749450","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532749450?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:30","pubTimestamp":1746102600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUA3JJZXR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KRON"],"gpt_icon":0},{"id":"2532074504","title":"Kronos Bio Enters Into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2532074504","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532074504?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:30","pubTimestamp":1746102600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUA3JJZXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KRON","BK4139"],"gpt_icon":0},{"id":"2520931329","title":"Kronos Bio Q4 2024 GAAP EPS $(0.43) Misses $(0.38) Estimate, Sales $2.270M Miss $2.420M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931329","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931329?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:03","pubTimestamp":1742328213,"startTime":"0","endTime":"0","summary":"Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is unchanged from the same period last year.  The company reported","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44384645/kronos-bio-q4-2024-gaap-eps-0-43-misses-0-38-estimate-sales-2-270m-miss-2-420m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRON","KRO"],"gpt_icon":0},{"id":"2520316931","title":"BRIEF-Kronos Bio Q4 EPS USD -0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2520316931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520316931?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:01","pubTimestamp":1742328105,"startTime":"0","endTime":"0","summary":"BRIEF-Kronos Bio Q4 EPS USD -0.43\n\n\nMar 18 (Reuters) - Kronos Bio Q4 operating expenses USD 29.424 million.\n\nQ4 net income USD -25.813 million\nQ4 operating income USD -27.154 million\nQ4 basic EPS USD -0.43","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLXB6ACA2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRON"],"gpt_icon":0},{"id":"2520393137","title":"Kronos Bio Inc - Q4 2024 Impairment and Restructuring Charges at $16.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520393137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520393137?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:01","pubTimestamp":1742328060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLXB6ACA2:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","KRON"],"gpt_icon":0},{"id":"2520318719","title":"Kronos Bio Q4 Operating Expenses USD 29.424 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520318719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520318719?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:01","pubTimestamp":1742328060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLXB6ACA2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KRON","BK4505"],"gpt_icon":0},{"id":"2494804631","title":"Kronos Bio, Genentech to Terminate Research Partnership; Shares Down Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2494804631","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494804631?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:24","pubTimestamp":1735302248,"startTime":"0","endTime":"0","summary":"Kronos Bio  said in a filing Friday it has agreed to terminate a collaboration and license agreement with Genentech, voiding Kronos' rights to all intellectual property generated under two discovery research programs under the partnership.Kronos said it will transfer to Genentech all small molecule compounds, materials and data generated in connection with the programs, excluding Kronos' proprietary drug discovery platform.The company also said it has made a one-time payment for the termination but did not disclose its figure.Shares of the company were down over 4% in recent Friday premarket activity.Price: 0.88, Change: -0.04, Percent Change: -4.35","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4090","BK4505","BK4139","KRO","KRON"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kronosbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.0736},{"period":"ytd","weight":-0.0737}],"compareEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.007714},{"month":2,"riseRate":0.2,"avgChangeRate":-0.09988},{"month":3,"riseRate":0.4,"avgChangeRate":-0.020409},{"month":4,"riseRate":0.4,"avgChangeRate":-0.083263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.155327},{"month":6,"riseRate":0.6,"avgChangeRate":0.172583},{"month":7,"riseRate":0.75,"avgChangeRate":0.043094},{"month":8,"riseRate":0.25,"avgChangeRate":-0.123369},{"month":9,"riseRate":0.25,"avgChangeRate":-0.068143},{"month":10,"riseRate":0,"avgChangeRate":-0.172004},{"month":11,"riseRate":0.4,"avgChangeRate":-0.031877},{"month":12,"riseRate":0.4,"avgChangeRate":-0.002966}],"exchange":"NASDAQ","name":"Kronos Bio, Inc.","nameEN":"Kronos Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kronos Bio, Inc.(KRON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kronos Bio, Inc.(KRON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kronos Bio, Inc.,KRON,Kronos Bio, Inc.股票,Kronos Bio, Inc.股票老虎,Kronos Bio, Inc.股票老虎国际,Kronos Bio, Inc.行情,Kronos Bio, Inc.股票行情,Kronos Bio, Inc.股价,Kronos Bio, Inc.股市,Kronos Bio, Inc.股票价格,Kronos Bio, Inc.股票交易,Kronos Bio, Inc.股票购买,Kronos Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kronos Bio, Inc.(KRON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kronos Bio, Inc.(KRON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction